For all the bulls who were behind $GLAS I really haven't seen any commenting on the current decline in the stock here. Has the fundamental thesis changed for some reason or is this collapse just technical?
If anything is K-shaped today, it’s the college admissions landscape. Top schools have never been more competitive to get into, while at the other end of the spectrum, some schools are admitting students who haven’t even applied.
wsj.com/us-news/education/hu…
In conclusion, DEA asked the judge overseeing the hearing to “expeditiously recommend” that marijuana be transferred from Schedule I to Schedule III.
$MSOS
👀👀👀
NEW: Marijuana Moment obtained all final briefs filed by parties in the Drug Enforcement Administration's cannabis rescheduling hearing—with DEA pointing out that the opposition's own witnesses "supported the therapeutic use of marijuana in certain instances" and anti-reform groups expressing concerns about process, public health and safety.
marijuanamoment.net/dea-and-…
While $VREO.CN may not be the first company to pursue a roll-up strategy, the speed and breadth of its acquisitions are certainly unusual. A few years from now, we'll likely look back on this as either one of the greatest roll-up success stories or one of the most spectacular destructions of shareholder capital.
#cannabis
globenewswire.com/news-relea…
Hopefully the market starts to appreciate the attractive opportunity at $BFIT.
Basic-Fit Raised to Buy at UBS; PT 43.50 euros
2026-06-09 15:55:06 GMT
(Bloomberg) -- UBS analyst Natasha Brilliant raised the
recommendation on Basic-Fit NV to buy from neutral.
PT set to 43.50 euros, implies a 49% increase from last price.
If $TSLA can trade at 120x T12M EBITDA I'm sure SpaceX can trade for an absurd valuation too.
Since $VREOF announced its recap in Dec ’24, shares are down ~30% vs. +35% for $MSOS. The roll-up hasn’t resonated with the market, and lock-up expirations still lie ahead.
investors.vireogrowth.com/ne…
Revelations Partners, LP retweeted
but but but AI
$FLYW
$FDX increasingly looks like an interesting short here. Valuation is near historical highs, fundamentals are solid but not exceptional, and a major 3PL is entering the space. Feels like multiple compression risk, similar to what we saw in software. Would welcome the bull case. $UPS $AMZN
Any reason $FDX is not a good short here at 20x?
wsj.com/logistics-report/ama…
Any reason $FDX is not a good short here at 20x?
wsj.com/logistics-report/ama…
With rescheduling momentum building, how are you thinking about upside in your #cannabis holdings? What P/E multiple does the sector re-rate to? (Broad strokes.)
23%Sub-10x (no interest)
45%15x (low growth consumer)
18%20x (growth story)
14%25x+ (meme fever)
22 votes • Final resultsDisappointing to see pieces like this get front-page treatment in outlets like @WSJ. No one is advocating for adolescent #cannabis use, just as no one in alcohol argues for lowering the drinking age. Feels like outdated scare tactics.
$MSOS $GTBIF $TCNNF $CXXIF $AAWH $CURLF
wsj.com/opinion/marijuana-is…
Hard to ignore that $TCNNF and Kim appeared closest to the administration among $MSOS CEOs. If this plays out, they could be among the primary beneficiaries and best positioned to act early.
#cannabis
Arguably @Trulieve is the largest immediate beneficiary of this initial ruling, given their outsized exposure to state-medical sales in Florida relative to their overall business (whereas peers have far more adult-use exposure) and the potential reduction in their UTP












